Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
Recruiting · NCT03945305 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.Previous antihypertensive treatment
What this trial is about
The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
Who can take part
Age range
30 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age≥30 years, ≤ 75 years, regardless of sex;
- Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment.
- Signed and dated informed consent is obtained.
Exclusion criteria
- Blood pressure ≥ 180/110mmHg;
- Planned adjustment of antihypertensive drugs within the next 3 weeks;
- Severe hematologic disorders or significant coagulation abnormalities;
- Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
- Pregnant or lactating women;
- Severe hepatic and renal dysfunction;
- Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
- Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.
Where it is running
1 location listed.
- First Hospital of Jilin University - Changchun, Jilin, China